Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists (Q37633537)

21 August 2017

1 reference

title

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists (English)

1 reference

21 August 2017

0 references

1 reference

John D Isaacs

1

0 references

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1463-1475

1 reference

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

A review of the MHC genetics of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

A two-step, two-signal model for the primary activation of precursor helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

T-cell regulation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Patient preferences for treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903379494

10.1517/14712590903379494

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference